Use of Altabax Ointment (Retapamulin 1%) BID for 7 Days in Treatment of Secondary Infection With Staphylococcus Aureus (MRSA and MSSA) and Streptococcus Pyogenes in Atopic Dermatitis Patients - Open Label Pilot Study

Trial Profile

Use of Altabax Ointment (Retapamulin 1%) BID for 7 Days in Treatment of Secondary Infection With Staphylococcus Aureus (MRSA and MSSA) and Streptococcus Pyogenes in Atopic Dermatitis Patients - Open Label Pilot Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Sep 2016

At a glance

  • Drugs Retapamulin (Primary)
  • Indications Atopic dermatitis; Methicillin-resistant Staphylococcus aureus infections; Staphylococcal infections; Streptococcal infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Apr 2012 Actual patient number is 29 as reported by ClinicalTrials.gov.
    • 02 Apr 2012 Actual end date (1 Jan 2012) added as reported by ClinicalTrials.gov.
    • 02 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top